Evaluation of the Crocin effect on the contrast induced nephropathy following coronary angiography or angioplasty: A randomized controlled trial

This study was designed and conducted to evaluate crocin’s efficacy in prevention of contrast induced nephropathy in CKD patients undergoing coronary angiography/angioplasty. In this randomized clinical trial, a total of one hundred and ten eligible CKD stage3 patients requiring contrast agent administration for coronary angiography/angioplasty were enrolled and randomly assigned to either crocin (n=57) or control group (n= 53). Patients in both groups received standard hydration therapy while in crocin group, they also were orally administered three consecutive oral doses of 30 mg crocin tablets from one day before till 1 day after the contrast media exposure. The primary end point was Contrast induced nephropathy incidence defined as an increase in SCr level by≥0.3 mg/dl or any change in urinary NGAL from baseline within 48 hours of contrast media exposure. During four months, 130 patients were recruited. The mean age of our patients was 65.62±9.05, and the majority of them was male (64.54%). The serum creatinine in the crocin group did not significantly increase within 48 of angiography/angioplasty. The changes in the urine NGAL level were not significant in both groups. Contrast induced nephropathy incidence was significantly lower in the crocin group than control group (1.75 % vs 13.2 %, p: 0.0028). Crocin administration play an important nephron-protective role in prevention of the contrast induced nephropathy.
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research